Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 08, 2022

SELL
$25.33 - $34.25 $156,995 - $212,281
-6,198 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$28.51 - $32.9 $176,704 - $203,914
6,198 New
6,198 $200,000
Q3 2021

Nov 12, 2021

SELL
$23.54 - $31.39 $170,194 - $226,949
-7,230 Closed
0 $0
Q2 2021

Aug 12, 2021

SELL
$26.72 - $33.19 $13,279 - $16,495
-497 Reduced 6.43%
7,230 $223,000
Q1 2021

May 14, 2021

BUY
$24.15 - $31.45 $186,607 - $243,014
7,727 New
7,727 $202,000
Q2 2019

Jul 18, 2019

SELL
$29.96 - $38.87 $321,620 - $417,269
-10,735 Closed
0 $0
Q1 2019

Apr 18, 2019

BUY
$32.77 - $41.99 $351,785 - $450,762
10,735 New
10,735 $376,000
Q4 2018

Jan 25, 2019

SELL
$30.84 - $49.51 $193,243 - $310,229
-6,266 Closed
0 $0
Q3 2018

Oct 17, 2018

SELL
$42.7 - $56.55 $367,091 - $486,160
-8,597 Reduced 57.84%
6,266 $275,000
Q2 2018

Jul 27, 2018

BUY
$44.1 - $59.85 $415,069 - $563,308
9,412 Added 172.67%
14,863 $890,000
Q1 2018

Apr 06, 2018

BUY
$37.15 - $46.9 $202,504 - $255,651
5,451 New
5,451 $250,000

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.94B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Eqis Capital Management, Inc. Portfolio

Follow Eqis Capital Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eqis Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Eqis Capital Management, Inc. with notifications on news.